Τίτλος:
MABp1 targeting interleukin-1α in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open-label extension period
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Δεν υπάρχει περίληψη
Συγγραφείς:
Kanni, T.
Argyropoulou, M.
Dinarello, C.A.
Simard, J.
Giamarellos-Bourboulis, E.J.
Περιοδικό:
CLINICAL AND EXPERIMENTAL DERMATOLOGY
Εκδότης:
Wiley-Blackwell Publishing Ltd
Λέξεις-κλειδιά:
adalimumab; bermekimab; interleukin 1alpha; placebo; adalimumab; IL1A protein, human; interleukin 1alpha; MABp1 monoclonal antibody; monoclonal antibody, clinical article; controlled study; disease exacerbation; double blind procedure; drug efficacy; drug targeting; follow up; human; Letter; open study; patient-reported outcome; phase 2 clinical trial; priority journal; randomized controlled trial; suppurative hidradenitis; chemistry; drug tolerance; intravenous drug administration; metabolism; organization and management; phase 2 clinical trial (topic); randomized controlled trial (topic); safety; suppurative hidradenitis; treatment outcome, Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials, Phase II as Topic; Drug Tolerance; Eligibility Determination; Hidradenitis Suppurativa; Humans; Infusions, Intravenous; Interleukin-1alpha; Patient Reported Outcome Measures; Placebos; Randomized Controlled Trials as Topic; Safety; Treatment Outcome
